WebSite Logo
  • Content
  • Similar Resources
  • Metadata
  • Cite This
  • Log-in
  • Fullscreen
Log-in
Do not have an account? Register Now
Forgot your password? Account recovery
  1. Expert Review of Anticancer Therapy
  2. Year: 2009 Volume: 9
  3. Year: 2009 Volume: 9 Issue: 1
  4. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.
Loading...

Please wait, while we are loading the content...

Year: 2017 Volume: 17
Year: 2017
Year: 2016 Volume: 16
Year: 2015 Volume: 15
Year: 2014 Volume: 14
Year: 2013 Volume: 13
Year: 2012 Volume: 12
Year: 2011 Volume: 11
Year: 2010 Volume: 10
Year: 2009 Volume: 9
Year: 2009 Volume: 9 Issue: 12
Year: 2009 Volume: 9 Issue: 11
Year: 2009 Volume: 9 Issue: 10
Year: 2009 Volume: 9 Issue: 9
Year: 2009 Volume: 9 Issue: 8
Year: 2009 Volume: 9 Issue: 7
Year: 2009 Volume: 9 Issue: 6
Year: 2009 Volume: 9 Issue: 5
Year: 2009 Volume: 9 Issue: 4
Year: 2009 Volume: 9 Issue: 3
Year: 2009 Volume: 9 Issue: 2
Year: 2009 Volume: 9 Issue: 1
Promises and challenges of human papillomavirus vaccines for cervical cancer.
New developments in targeted molecular therapies for glioblastoma.
The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.
Year: 2008 Volume: 8
Year: 2007 Volume: 7

Similar Documents

...
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.

Article

...
Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.

Article

...
Another selective estrogen-receptor modulator for osteoporosis.

Article

...
The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.

Article

...
Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.

Article

...
The use of raloxifene in osteoporosis treatment.

Article

...
Beyond raloxifene for the prevention of osteoporosis and breast cancer.

Article

...
Altering the propensity for density: the benefits and risks of selective estrogen receptor modulators.

Article

...
Ospemifene for the treatment of dyspareunia in postmenopausal women.

Article

The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.

Content Provider World Health Organization (WHO)-Global Index Medicus
Author Vogel, Victor G.
Description Country affiliation: United States Author Affiliation: Vogel VG ( University of Pittsburgh Cancer Institute, Magee-Womens Hospital, Pittsburgh, PA 15213-3180, USA. vvogel@magee.edu)
Abstract In the Study of Tamoxifen and Raloxifene (STAR) trial, postmenopausal women at increased risk of breast cancer received either oral tamoxifen (20 mg/day) or raloxifene (60 mg/day) over 5 years. There were an equal number of cases of invasive breast cancer in women assigned to tamoxifen and raloxifene. There were fewer cases of noninvasive breast cancer in the tamoxifen group than in the raloxifene group (risk ratio [RR]: 1.40; 95% confidence interval [CI]: 0.98-2.02). There were more cases of uterine cancer with tamoxifen than with raloxifene (RR: 0.62; 95% CI: 0.35-1.08). Thromboembolic events occurred less often in the raloxifene group (RR: 0.70; 95% CI: 0.54-0.91) and there were fewer cataracts and cataract surgeries in the women taking raloxifene (RR: 0.79; 95% CI: 0.68-0.92). The STAR trial has shown that raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of adverse events but a nonstatistically significant higher risk of noninvasive breast cancer. The risk of other cancers, fractures, ischemic heart disease and stroke is similar for both drugs.
File Format HTM / HTML
ISSN 14737140
e-ISSN 17448328
DOI 10.1586/14737140.9.1.51
Journal Expert Review of Anticancer Therapy
Issue Number 1
Volume Number 9
Language English
Publisher Taylor & Francis
Publisher Date 2009-01-01
Publisher Place Great Britain (UK)
Access Restriction Open
Subject Keyword Discipline Therapeutics Discipline Oncology Raloxifene Therapeutic Use Selective Estrogen Receptor Modulators Tamoxifen Breast Neoplasms Epidemiology Pathology Osteoporosis Prevention & Control Postmenopause Adverse Effects
Content Type Text
Resource Type Article
Subject Pharmacology (medical) Oncology
  • About
  • Disclaimer
  • Feedback
  • Sponsor
  • Contact
  • Chat with Us
About National Digital Library of India (NDLI)
NDLI logo

National Digital Library of India (NDLI) is a virtual repository of learning resources which is not just a repository with search/browse facilities but provides a host of services for the learner community. It is sponsored and mentored by Ministry of Education, Government of India, through its National Mission on Education through Information and Communication Technology (NMEICT). Filtered and federated searching is employed to facilitate focused searching so that learners can find the right resource with least effort and in minimum time. NDLI provides user group-specific services such as Examination Preparatory for School and College students and job aspirants. Services for Researchers and general learners are also provided. NDLI is designed to hold content of any language and provides interface support for 10 most widely used Indian languages. It is built to provide support for all academic levels including researchers and life-long learners, all disciplines, all popular forms of access devices and differently-abled learners. It is designed to enable people to learn and prepare from best practices from all over the world and to facilitate researchers to perform inter-linked exploration from multiple sources. It is developed, operated and maintained from Indian Institute of Technology Kharagpur.

Learn more about this project from here.

Disclaimer

NDLI is a conglomeration of freely available or institutionally contributed or donated or publisher managed contents. Almost all these contents are hosted and accessed from respective sources. The responsibility for authenticity, relevance, completeness, accuracy, reliability and suitability of these contents rests with the respective organization and NDLI has no responsibility or liability for these. Every effort is made to keep the NDLI portal up and running smoothly unless there are some unavoidable technical issues.

Feedback

Sponsor

Ministry of Education, through its National Mission on Education through Information and Communication Technology (NMEICT), has sponsored and funded the National Digital Library of India (NDLI) project.

Contact National Digital Library of India
Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302
See location in the Map
03222 282435
Mail: support@ndl.gov.in
Sl. Authority Responsibilities Communication Details
1 Ministry of Education (GoI),
Department of Higher Education
Sanctioning Authority https://www.education.gov.in/ict-initiatives
2 Indian Institute of Technology Kharagpur Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project https://www.iitkgp.ac.in
3 National Digital Library of India Office, Indian Institute of Technology Kharagpur The administrative and infrastructural headquarters of the project Dr. B. Sutradhar  bsutra@ndl.gov.in
4 Project PI / Joint PI Principal Investigator and Joint Principal Investigators of the project Dr. B. Sutradhar  bsutra@ndl.gov.in
Prof. Saswat Chakrabarti  will be added soon
5 Website/Portal (Helpdesk) Queries regarding NDLI and its services support@ndl.gov.in
6 Contents and Copyright Issues Queries related to content curation and copyright issues content@ndl.gov.in
7 National Digital Library of India Club (NDLI Club) Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach clubsupport@ndl.gov.in
8 Digital Preservation Centre (DPC) Assistance with digitizing and archiving copyright-free printed books dpc@ndl.gov.in
9 IDR Setup or Support Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops idr@ndl.gov.in
I will try my best to help you...
Cite this Content
Loading...